Tin tức & Cập nhật
Xem bài viết Hô hấp
Xem

Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC
Use of anlotinib combined with etoposide and carboplatin (EC; chemotherapy) as first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) yields a significantly improved progression-free survival (PFS) as well as overall survival (OS) benefits when compared with chemotherapy, according to data from the phase III ETER701 trial presented at ELCC 2024.

Amivantamab plus chemo tied to better outcomes in NSCLC
Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.




![[Infographic] Thảo luận bàn tròn - Bệnh nhân COPD giai đoạn ổn định: nên điều trị những gì?](https://cdn.mspprd.mims.com/images/articles/thao-luan-ban-tron-benh-nhan-copd-giai-đoan-on-đinh-nen-đieu-tri-nhung-gi-banner-64f42148-bd29-492e-a945-988eb34dca28-square.jpg)
![[Infographic] Thảo luận bàn tròn - Kết hợp bộ đôi hay bộ ba trong COPD?](https://cdn.mspprd.mims.com/images/articles/thao-luan-ban-tron-ket-hop-bo-đoi-hay-bo-ba-trong-copd-banner-ee1a6635-0c80-470a-af36-f01dd6b8abd5-square.jpg)
![[Infographic] Một số điểm chính về Hội nghị khoa học COPD lần 3 - Phiên toàn thể](https://cdn.mspprd.mims.com/images/articles/mot-so-điem-chinh-ve-hoi-nghi-khoa-hoc-copd-lan-3-phien-toan-the-banner-2eee2abb-90bb-4f32-8a75-1334a483b027-square.jpg)